Carregant...
The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker
Tumor mutational burden (TMB) reflects cancer mutation quantity. Mutations are processed to neo-antigens and presented by major histocompatibility complex (MHC) proteins to T-cells. To evade immune eradication, cancers exploit checkpoints that dampen T-cell reactivity. Immune checkpoint inhibitors (...
Guardat en:
| Publicat a: | Cancer Cell |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7878292/ https://ncbi.nlm.nih.gov/pubmed/33125859 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2020.10.001 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|